Search results for "carrier state"

showing 10 items of 38 documents

Frequency of CD8+ T Lymphocytes Specific for Lytic and Latent Antigens of Epstein–Barr Virus in Healthy Virus Carriers

1999

Abstract We investigated CD8 + T cell frequencies of five different Epstein–Barr virus-specific cytotoxic T lymphocyte epitopes located within proteins of the replicative cycle and the latent state in healthy long-term virus carriers with IFN-γ enzyme-linked immunospot assay. Frequencies of the HLA-A3-restricted epitope RVRAYTYSK (RVR) whose minimal length was mapped in this study to amino acid position 148–156 of the immediate-early protein BRLF1 were compared with those of a further known HLA-A3-restricted epitope within EBNA3A, RLRAEAQVK (RLR). Determination of frequencies of CD8 + T lymphocytes directed against lytic antigen epitope RVR revealed that only one of eight donors recognized …

Epstein-Barr Virus InfectionsHerpesvirus 4 HumanvirusesT cellEpitopes T-LymphocyteCD8-Positive T-LymphocytesBiologymedicine.disease_causeVirusEpitopeCell LineImmediate-Early ProteinsViral ProteinsAntigenVirologymedicineHumansCytotoxic T cellHematopoietic Stem CellsEpstein–Barr virusVirologyMolecular biologyBZLF1medicine.anatomical_structureEpstein-Barr Virus Nuclear AntigensCarrier StateTrans-ActivatorsCD8T-Lymphocytes CytotoxicVirology
researchProduct

Relationship of pre-S encoded antigens in liver and clinical manifestations of chronic hepatitis B infection.

2008

Pre-S1 and pre-S2 encoded antigens of hepatitis B virus were localized in liver tissue using monoclonal antibodies. They were found to be exclusively expressed in the cytoplasm of liver cells. Cell bound pre-S1 encoded protein was often detected in patients with chronic liver disease and viremia. Only a small number of the HBsAg positive cells also contained pre-S1 antigen. There was no correlation with nuclear HBcAg. Livers of non-viremic HBsAg carriers contained many HBsAg expressing liver cells, that were frequently also positive for pre-S2 encoded protein but contained no detectable pre-S1 encoded protein at all. It remains open whether cell bound pre-S2 containing proteins of middle si…

HBsAgHepatitis B virusBiopsyRadioimmunoassayViremiaBiologyChronic liver diseaseImmunoenzyme Techniques03 medical and health sciencesLiver disease0302 clinical medicineAntigenmedicineHumans030304 developmental biologyHepatitis0303 health sciencesHepatitis B Surface AntigensHepatologyvirus diseasesmedicine.diseasebiology.organism_classificationHepatitis BVirology3. Good healthHBcAgHepadnaviridaeLiverImmunologyCarrier State030211 gastroenterology & hepatologyLiver
researchProduct

The diagnostic significance of intrahepatocellular hepatitis-B-surface-antigen (HB s Ag), hepatitis-B-core-antigen (HB c Ag) and IgG for the classifi…

1975

Liver biopsies of patients with inflammatory liver diseases and clinically healthy HBsAg-carriers were examined for presence of intracellular HBsAg, HBcAg and IgG by direct immunofluorescence. The studies revealed the following results: 1. In most cases healthy HBsAg-carriers had HBsAg in the cytoplasm, but they did never show HBcAg in the nuclei of hepatocytes. 2. In the early phase some patients with HBsAg-positive acute hepatitis had HBcAg and/or HBsAg in their hepatocytes. In a normal course with complete recovery the immunoelimination may clear either phenomenon at variable stages of the disease. 3. Cases one year after complete recovery of acute virus B-hepatitis had no HB-components …

HBsAgVirusHepatitis B AntigensAntigenDrug DiscoverymedicineHumansDirect fluorescent antibodyGenetics (clinical)Cell NucleusHepatitismedicine.diagnostic_testbusiness.industryLiver cellvirus diseasesGeneral MedicineHepatitis Amedicine.diseasedigestive system diseasesHBcAgLiverVirus DiseasesImmunoglobulin GLiver biopsyAcute DiseaseCarrier StateChronic DiseaseImmunologyMolecular MedicinebusinessKlinische Wochenschrift
researchProduct

Prophylaxis and treatment of hepatitis B in immunocompromised patients.

2007

The literature on hepatitis B virus (HBV) in immunocompromised patients is heterogeneous and referred mainly to the pre-antivirals era. Today a rational approach to the problem of hepatitis B in these patients provides for: (a) the evaluation of HBV markers and of liver condition in all subjects starting immunosuppressive therapies (baseline), (b) the treatment with antivirals (therapy) of active carriers, (c) the pre-emptive use of antivirals (prophylaxis) in inactive carriers, especially if they are undergoing immunosuppressive therapies judged to be at high risk, (d) the biochemical and hepatitis B surface antigen (HBsAg) monitoring (or universal prophylaxis, in case of high risk immunos…

HBsAgmedicine.medical_specialtyHepatitis C virusmedicine.medical_treatmentLiver transplantationTransplantmedicine.disease_causeGastroenterologyAntiviral AgentsImmunocompromised HostAnimals; Antiviral Agents; Carrier State; Hepatitis B; Hepatitis B Core Antigens; Hepatitis B Surface Antigens; Humans; Immunocompromised Host; Liver Transplantation; Tissue Donors; TransplantationAntivirals; HBV; Immunosuppression; Transplants;Internal medicineHBVMedicineAnimalsHumansAntiviralHepatitis B virusTransplantationHepatitis B Surface AntigensHepatologybusiness.industryGastroenterologyvirus diseasesHepatitis Bmedicine.diseaseHepatitis BHepatitis B Core Antigensdigestive system diseasesTissue DonorsLiver TransplantationTransplantationHBeAgImmunologyCarrier StateHepatitis D virusbusinessImmunosuppression
researchProduct

e System and intrahepatocelullar HBcAG and HBsAG in HBsAG positive patients with liver diseases and healthy carriers.

1977

Patients with hepatitis-B surface antigen positive liver diseases and healthy carriers were studied for the presence of e-antigen and anti-e as well as for intrahepatocellular HBsAG and hepatitis-B core antigen. The e-antigen was demonstrated in 9 out of 12 patients with chronic perisitent hepatitis, in 15 out of 39 patients with chronic active hepatitis, in 3 out of 40 patients with acute type B hepatitis, and in 2 out of 9 patients with a protracted course of type B hepatitis. No e-antigen was found in healthy HBsAG carriers nor in patients with complete recovery from type B hepatitis one year after onset of the disease. Anti-e was detected in 24 out of 61 healthy HBsAG carriers with a no…

HepatitisHBsAgChronic Activebusiness.industryLiver cellLiver DiseasesGastroenterologyChronic persistent hepatitisDiseasemedicine.diseaseHepatitis BHepatitis B Core AntigensHepatitisHepatitis B AntigensHBcAgAntigenLiverImmunologyAcute DiseaseCarrier StateChronic DiseasemedicineHumansAntigensbusinessScandinavian journal of gastroenterology
researchProduct

The asialoglycoprotein receptor mediates hepatic binding and uptake of natural hepatitis B virus particles derived from viraemic carriers.

1994

As a putative mechanism of hepatitis B virus (HBV) uptake into hepatocytes the interaction between HBV and the hepatic, human-derived asialoglycoprotein receptor (ASGPR) was investigated. Sera from patients with different variations of hepatitis B surface antigen-(HBsAg) positive chronic hepatitis, HBV particles isolated from HBV carriers with high-titre viraemia and commercial HBsAg served as sources of HBV. ASGPR was affinity-purified from human liver. HBV that had bound to isolated ASGPR was either detected by radio-immunoassay using solid-phase bound ASGPR or enzyme immunoassay with biotin-ASGPR bound to immobilized HBV. Furthermore, binding and uptake of purified, 125I-labelled HBV par…

HepatoblastomaHBsAgHepatitis B virusCarcinoma HepatocellularAsialoglycoproteinsReceptors Cell SurfaceAsialoglycoprotein Receptormedicine.disease_causeBinding CompetitiveVirusVirologymedicineTumor Cells CulturedHumansHepatitis B e AntigensViremiaBinding siteHepatitis B virusCOS cellsHepatitis B Surface AntigensbiologyCell MembraneLiver Neoplasmsvirus diseasesBlood ProteinsHepatitis Bmedicine.diseaseHepatitis BVirologyMolecular biologydigestive system diseasesLiverAcute DiseaseCarrier StateChronic Diseasebiology.proteinReceptors VirusAsialoglycoprotein receptorAntibodyThe Journal of general virology
researchProduct

β-Thalassemia heterozygote state detrimentally affects health expectation.

2018

Background: Thalassemia minor (Tm) individuals, are generally considered healthy. However, the prognosis of Tm individuals has not been extensively studied. The aim of this study was to evaluate the prognosis of Tm versus controls without β-thalassemia carrier state. Methods: A total of 26,006 individuals seeking thalassemia screening at the AOOR Villa Sofia-V. Cervello, Palermo (Italy) were retrospectively studied. Logistic penalised regression model was used to estimate risk of potential complications and survival techniques were used to study mortality. Results: We identified a total of 4943 Tm and 21,063 controls. Tm was associated with significantly higher risks of hospitalisation for …

Liver Cirrhosismedicine.medical_specialtyHeterozygoteCirrhosisThalassemia MinorThalassemia030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineβ-Thalassemia carrier stateLife ExpectancyCholelithiasisInternal medicineInternal MedicineMedicineHumansMortalityThalassemia minorHealth expectationbusiness.industryMood DisordersCarrier statebeta-ThalassemiaHeterozygote advantagemedicine.diseaseHospitalizationThalassemia screeningLogistic ModelsMood disordersItalyKidney DiseasesKidney disorderbusiness030215 immunologyEuropean journal of internal medicine
researchProduct

Using a Multi-Locus Microsatellite Typing method improved phylogenetic distribution of Candida albicans isolates but failed to demonstrate associatio…

2012

EA MERS CT3 Enjeu 3; International audience; The dimorphic yeast Candida albicans is a component of the normal microflora at the mucosal surfaces of healthy individuals. It possesses an array of phenotypic properties considered as virulence traits that contribute to pathogenicity of the yeast in immuno-compromised patients. We addressed the question of the pathogenicity of lineages of C. albicans with regard to their genotype in three series of C. albicans isolates (a series of commensal isolates collected in healthy individuals, a group of bloodstream isolates and a group of non-bloodstream clinical isolates) using a Multi-Locus Microsatellite Typing (MLMT) approach based on the analysis o…

MESH: Genetic MarkersMESH : Microsatellite RepeatsMESH : CandidiasisGenotypeCandida albicansMESH : Genetic MarkersDNA FungalMycological Typing TechniquesCandida albicansMESH : Mycological Typing TechniquesMESH: PhylogenyPhylogeny[ SDV.MP.MYC ] Life Sciences [q-bio]/Microbiology and Parasitology/Mycology[SDV.MP.MYC]Life Sciences [q-bio]/Microbiology and Parasitology/MycologyGenetics0303 health sciencesbiologyCandidiasisFungal geneticsAllelic frequenciesMESH: Case-Control StudiesCorpus albicansMESH: CandidiasisInfectious DiseasesMESH : Carrier StateCarrier StateMicrosatelliteMESH: Carrier StateGenetic MarkersMicrobiology (medical)MESH : Case-Control StudiesGenotypingMESH : Candida albicansGenes FungalMicrobiologyMicrobiology03 medical and health sciencesMESH: Mycological Typing TechniquesGeneticsHumansPathogenicityTypingLineagesMolecular BiologyEcology Evolution Behavior and Systematics030304 developmental biologyMESH: Humans030306 microbiologyMESH: Candida albicansMESH : HumansUPGMAMESH : Phylogenybiology.organism_classificationMESH: DNA FungalCase-Control StudiesMultilocus sequence typingMLMTMESH : Genes FungalMESH: Microsatellite RepeatsMESH : DNA FungalMESH: Genes FungalMicrosatellite Repeats
researchProduct

Detection of hepatitis B virus markers in sera of asymptomatic hepatitis B surface antigen carriers with special emphasis to pre-S-encoded proteins.

1987

Sera of asymptomatic hepatitis B surface antigen (HBsAg) carriers were analyzed for the presence of pre-S-encoded proteins. Four individuals with biopsy-proven chronic hepatitis uniformly expressed pre-S1- and pre-S2-encoded proteins. Individuals who had histologically normal or largely normal livers were heterogeneous with respect to expression of pre-S-encoded proteins. This heterogeneous expression of pre-S-encoded proteins occurred most likely due to difference in serum HBsAg concentration. Alternatively differences in pre-S gene expression need to be considered. Clinically the study indicates that expression of pre-S domains in serum is unrelated to viremia or chronic liver disease.

MaleHBsAgHepatitis B virusViremiamedicine.disease_causeChronic liver diseaseAsymptomaticGene expressionmedicineHumansProspective StudiesHepatitis B virusHepatitis B Surface Antigensbiologybusiness.industryGastroenterologyHepatitis Bmedicine.diseaseVirologyImmunologyCarrier StateDNA Viralbiology.proteinFemalemedicine.symptomAntibodybusinessDigestion
researchProduct

Hepatitis B Virus DNA in Liver Tissue of Chronic HBsAg Carriers in Childhood and Its Relationship to Other Viral Markers

1992

The aim of the study was to examine the state of hepatitis B virus (HBV) DNA in liver tissue of 103 children with chronic hepatitis B aged 0.5-18 years to detect free and integrated viral sequences by Southern blot hybridization. HBV DNA was found in 74 patients. Seventy-two were seropositive for hepatitis B e antigen (HBeAg) and two had anti-HBe antibodies. Integrated sequences could be demonstrated in two children. One of them had only integrated HBV DNA and was anti-HBe seropositive. The other one presented both free and integrated viral sequences and developed seroconversion from HBeAg to anti-HBe 5 months after biopsy. In 29 hepatitis B surface antigen (HBsAg) carriers, no HBV DNA coul…

MaleHepatitis B virusHBsAgAdolescentHepatitis B virus DNA polymerasemedicine.disease_causeHumansMedicineSeroconversionChildSouthern blotHepatitis B virusHepatitis B Surface Antigensbusiness.industryLiver cellGastroenterologyInfantvirus diseasesHepatitis BVirologydigestive system diseasesBlotting SouthernLiverHBeAgChild PreschoolCarrier StateChronic DiseaseDNA ViralPediatrics Perinatology and Child HealthImmunologyFemalebusinessViral loadJournal of Pediatric Gastroenterology and Nutrition
researchProduct